Search with one or more keywords


This page gives you access to all the studies carried out by French researchers, identified on Covid-19.

To view other resources related to Covid-19, click here.


xml
XML

Export to XML

Please choose the format :

pdf
PDF

Export to PDF

Which version do you want to export ?

csv
CSV (Excel)

Export to CSV

What sections do you want to export ?

Métadonnées
Identification
General Aspects
Scientific investigator(s) (Contact)
Collaborations
Funding
Governance of the database
Additional contact
Type of database
Database objective
Population type
Dates
Size of the database
Data
Procedures
Promotion
Access
Select all | Invert selection | No selection

ARCHIVES : 309 forms

Sorting of results :

SISTOLA - Observational usage and effectiveness of candesartan in heart failure treatment in France

Head : Thomas-Delcourt Florence, AstraZeneca

Version 2
Overview

31

Last update : 01/01/2020

ARCHIVE

SISTOLA - Observational usage and effectiveness of candesartan in heart failure treatment in France

Head : Thomas-Delcourt Florence, AstraZeneca

Main objective

To describe the way candesartan is used in heart failure treatment in France (treatment initiation and follow-up) treatment discontinuation occurences and reasons why and patients clinical evolution

Inclusion criteria

Patients starting or who have recently started (less than 30 days) a treatment with candesartan for heart failure

DISCOVER - Screening for extracoronary atherothrombotic localizations after an acute coronary syndrome and clinical management of patients

Head : Herrmann Marie-Annick, Bristol-Myers Squibb
Schmidely Nathalie, Bristol-Myers Squibb

Version 1
Overview

32

Last update : 09/05/2017

ARCHIVE

DISCOVER - Screening for extracoronary atherothrombotic localizations after an acute coronary syndrome and clinical management of patients

Head : Herrmann Marie-Annick, Bristol-Myers Squibb
Schmidely Nathalie, Bristol-Myers Squibb

Main objective

Evaluate the frequency of uninvestigated and investigated patients in the detection of extra-coronary atherothrombotic locations in a population of patients having an history of ACS in the year preceding the selection visit and followed by office based cardiologists.

Inclusion criteria

M/F, >=18 years, examined in consultation by an office based cardiologist, with an history of ACS with or without ST-segment elevation in the 12 months preceding the selection

PLEIAD - Descriptive epidemiological study in nursing home

Head : Crochard Anne

Version 1
Overview

33

Last update : 01/01/2020

ARCHIVE

PLEIAD - Descriptive epidemiological study in nursing home

Head : Crochard Anne

Main objective

To describe the population of nursing home residents in France and in particular to quantify transitions into or out of the nursing home and to describe the characteristics of the nursing home residents at admission and discharge.

Inclusion criteria

To be eligible, the residents had to have been admitted to the nursing home for the first time (from home, hospital or another nursing home) or following a hospitalization, or had to have been temporarily or permanently discharged from the nursing home (to home, hospital or another nursing home) in the previous three months.

YZATIS - Evaluation et évolution de la prise en charge thérapeutique à moyen terme des patients séropositifs pour le VIH-1 traités avec une combinaison antirétrovirale incluant Atazanavir

Head : Bennai Yacia, Bristol-Myers Squibb
Schmidely Nathalie, Bristol-Myers Squibb

Version 1
Overview

34

Last update : 09/05/2017

ARCHIVE

YZATIS - Evaluation et évolution de la prise en charge thérapeutique à moyen terme des patients séropositifs pour le VIH-1 traités avec une combinaison antirétrovirale incluant Atazanavir

Head : Bennai Yacia, Bristol-Myers Squibb
Schmidely Nathalie, Bristol-Myers Squibb

Main objective

Describe the arrangements for caring for patients treated by a combination of treatments including ATAZANAVIR according to the grounds for introducing the treatment (virological failure of the previous treatment or other)

Inclusion criteria

M or F, aged 18 years or older, seropositive for HIV-1, treated via a combination of ARV treatments including ATV for which the main reason for introduction of the current treatment was: - virological failure of the previous treatment OR
- another reason.

APTOR - Prospective observational study of patients with acute coronary syndrome managed by PCI and antiplatelet treatment: Antiplatelet Treatment Observational Registry

Head : Médecin pharmacoépidémiologiste

Version 2
Overview

35

Last update : 01/01/2018

ARCHIVE

APTOR - Prospective observational study of patients with acute coronary syndrome managed by PCI and antiplatelet treatment: Antiplatelet Treatment Observational Registry

Head : Médecin pharmacoépidémiologiste

Main objective

Primary objective: evaluate the use of healthcare resources and cost in the 12 months following a percutaneous coronary intervention (PCI) combined with antiplatelet treatment in patients with acute coronary syndrome.
Secondary objectives: quality of life and clinical evolution.

Inclusion criteria

Be diagnosed with acute coronary syndrome,
- treatment with percutaneous coronary intervention in routine care;
- start or continue antiplatelet treatment.

EPIDOS - Risk Factors for Osteoporotic Fracture

Head : Dargent Patricia, U 953
Bréart , U953

Version 2
Overview

36

Last update : 09/05/2017

ARCHIVE

EPIDOS - Risk Factors for Osteoporotic Fracture

Head : Dargent Patricia, U 953
Bréart , U953

Main objective

General objective: to study the risk factors for osteoporotic fracture with a focus on femoral neck fracture

Inclusion criteria

Women over 75 years old included in electoral registers with no prior femoral fracture

Please wait...

Partners - FAQ - Contact - Site map - Legal notices - Administration - Updated on December 15 2020 - Version 4.10.05

View Edit Create here